A case of advanced gastric cancer showing HER2 positivity after chemotherapy

AbstractA 63-year-old man had advanced poorly differentiated gastric adenocarcinoma with para-aortic lymph node metastases. No HER2 expression was observed in four endoscopic biopsies from the primary tumor. Tumors shrunk after S-1 with cisplatin treatment, and he underwent simple gastrectomy due to stenosis. Interestingly, HER2 diffusely overexpressed in the resected surgical specimen. His disease was stable with trastuzumab-containing therapy for 6.4  months. This case may suggest a selection of HER2-positive cells that were insensitive to the chemotherapy, and further study is needed for the change of intratumoral HER2 heterogeneity after chemotherapy.
Source: International Cancer Conference Journal - Category: Cancer & Oncology Source Type: research

Related Links:

CONCLUSION: PTEN protein expression and KRAS mutations may predict disease outcome in early-stage gastric cancer. These results need to be further validated in larger cohorts. PMID: 32345669 [PubMed - in process]
Source: Genomics Proteomics ... - Category: Genetics & Stem Cells Authors: Tags: Cancer Genomics Proteomics Source Type: research
Conclusion: PTEN protein expression and KRAS mutations may predict disease outcome in early-stage gastric cancer. These results need to be further validated in larger cohorts.
Source: Cancer Genomics and Proteomics - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
CONCLUSION: Trastuzumab treatment in everyday practice as observed in HerMES confirmed the positive results of the pivotal study ToGA in an observational, real-world setting. IMPLICATIONS FOR PRACTICE: Real-world data of trastuzumab treatment of patients with gastroesophageal or gastric metastatic adenocarcinoma confirmed the positive results of the pivotal clinical trial. The observed median overall survival was 14.1 months and the median progression-free survival was 7.9 months. Although recommendations concerning administration of trastuzumab were well implemented, a high diversity of chemotherapy regimens were com...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
AbstractThe discovery of human epidermal growth factor receptor 2 (HER2) overexpression in 15 –20% of gastric adenocarcinomas has been a key advance in the global care of this disease. Validated by the ToGA trial in the first-line setting of advanced HER2-positive (+) gastric cancer (GC), trastuzumab, an anti-HER2 monoclonal antibody (mAb), was the first therapeutic agent to significantly improve the prognosis of these patients. Since these results, many attempts have been made to improve the clinical outcomes of patients with HER2+ GC. However, all the other HER2-targeting molecules have failed to show a survival be...
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
We describe the different evidences and recommendations following the statements of the American College of Physicians.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundAddition of trastuzumab to first-line palliative chemotherapy in gastroesophageal cancer patients with HER2 overexpression has shown to improve survival. Real-world data on HER2 assessment and administration of trastuzumab are lacking. The aim of this study was to assess HER2 testing, trastuzumab administration, and overall survival (OS) in a nationwide cohort of metastatic gastroesophageal cancer patients.MethodsData of patients with synchronous metastatic gastroesophageal adenocarcinoma diagnosed in 2010 –2016 that received palliative systemic treatment (n = 2846) were collected from...
Source: Gastric Cancer - Category: Gastroenterology Source Type: research
This study aimed to assess the proportion of HER2 positivity and its clinical implications in a large and well-characterized European GBC cohort. HER2 status was determined in 186 cases of surgically resecte d gallbladder adenocarcinoma and a subset of coexistent high-grade biliary intraepithelial neoplasia (BilIN,n = 74) in accordance with the up-to-date consensus for HER2 testing in gastric cancer by immunohistochemistry and dual-color chromogenic in situ hybridization. Positivity for HER2 was observed in 5.4% of all cases (n = 10). In those patients with concomitant high-grade BilIN, two of four positive samples also sh...
Source: Virchows Archiv - Category: Pathology Source Type: research
HER2, NF-κB, and SATB1 Expression Patterns in Gastric Cancer and Their Correlation with Clinical and Pathological Parameters. Dis Markers. 2019;2019:6315936 Authors: Smolińska M, Grzanka D, Antosik P, Kasperska A, Neska-Długosz I, Jóźwicki J, Klimaszewska-Wiśniewska A Abstract Gastric cancer (GC) is currently recognized as one of the most common and fatal tumor worldwide. The identification of novel biomarkers in relation to clinical information as well as extending the knowledge on a multiple crosstalk between various oncogenic pathways implicated in GC carcinogenesis seems pivotal to...
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Conferences | Gastrectomy | Gastric (Stomach) Cancer | Gastroenterology | HER2 | Herceptin | Study